Tenax Therapeutics, Inc. (NASDAQ:TENX) Short Interest Up 54.7% in June

Tenax Therapeutics, Inc. (NASDAQ:TENX) was the target of a significant growth in short interest in June. As of June 15th, there was short interest totalling 9,900 shares, a growth of 54.7% from the May 31st total of 6,400 shares. Approximately 0.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 32,700 shares, the days-to-cover ratio is presently 0.3 days.

Tenax Therapeutics Stock Up 1.0 %

Tenax Therapeutics stock opened at $3.01 on Monday. The company has a fifty day simple moving average of $3.45 and a 200-day simple moving average of $7.20. Tenax Therapeutics has a 52-week low of $2.77 and a 52-week high of $61.20.

Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($3.12) earnings per share for the quarter, missing the consensus estimate of ($2.40) by ($0.72). Equities analysts anticipate that Tenax Therapeutics will post -7.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of Tenax Therapeutics in a report on Sunday. They set a “sell” rating for the company.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.